

Qingyu Zeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8698810/publications.pdf>

Version: 2024-02-01

18
papers

282
citations

840119

11
h-index

940134

16
g-index

18
all docs

18
docs citations

18
times ranked

266
citing authors

#	ARTICLE	IF	CITATIONS
1	Modified 5-aminolevulinic acid photodynamic therapy reduces pain and improves therapeutic effects in cutaneous squamous cell carcinoma mouse model. <i>Lasers in Surgery and Medicine</i> , 2022, 54, 804-812.	1.1	8
2	PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2061396.	2.1	20
3	Single-cell transcriptomic analysis reveals the critical molecular pattern of UV-induced cutaneous squamous cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 23.	2.7	19
4	Ruyi Jinhuang Powder accelerated diabetic ulcer wound healing by regulating Wnt/ β 2-catenin signaling pathway of fibroblasts In Vivo and In Vitro. <i>Journal of Ethnopharmacology</i> , 2022, 293, 115321.	2.0	7
5	Molecular characterization of gene expression changes in murine cutaneous squamous cell carcinoma after 5-aminolevulinic acid photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, , 102907.	1.3	3
6	Celastrol inhibits LL37-induced rosacea by inhibiting Ca ²⁺ /CaMKII-mTOR-NF- κ B activation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113292.	2.5	9
7	5-Aminolaevulinic acid photodynamic therapy amplifies intense inflammatory response in the treatment of acne vulgaris via CXCL8. <i>Experimental Dermatology</i> , 2021, 30, 923-931.	1.4	18
8	Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) inhibits cutaneous squamous cell carcinoma cell proliferation via targeting PP2A/PP5-mediated MAPK signaling pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 137, 106036.	1.2	12
9	5-Aminolaevulinic acid photodynamic therapy suppresses lipid secretion of primary sebocytes through AMPK/SREBP-1 pathway. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 36, 102537.	1.3	7
10	Efficacy of the therapy of 5-aminolevulinic acid photodynamic therapy combined with human umbilical cord mesenchymal stem cells on methicillin-resistant <i>Staphylococcus aureus</i> -infected wound in a diabetic mouse model. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 36, 102480.	1.3	14
11	Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 37, 102572.	1.3	3
12	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca ²⁺ -CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. <i>Cell Calcium</i> , 2020, 87, 102171.	1.1	18
13	Antibacterial photodynamic therapy mediated by 5-aminolevulinic acid on methicillin-resistant <i>Staphylococcus aureus</i> . <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 28, 330-337.	1.3	19
14	BAFF inhibits autophagy promoting cell proliferation and survival by activating Ca ²⁺ -CaMKII-dependent Akt/mTOR signaling pathway in normal and neoplastic B-lymphoid cells. <i>Cellular Signalling</i> , 2019, 53, 68-79.	1.7	29
15	Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 516-529.	2.0	20
16	IL-2, IL-4, IFN- γ or TNF- α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. <i>Cytokine</i> , 2016, 84, 37-46.	1.4	14
17	Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4867-4884.	2.4	42
18	BAFF activates Erk1/2 promoting cell proliferation and survival by Ca ²⁺ -CaMKII-dependent inhibition of PP2A in normal and neoplastic B-lymphoid cells. <i>Biochemical Pharmacology</i> , 2014, 87, 332-343.	2.0	20